> Research Use Only Disclaimer: Pinealon (EDR tripeptide) is not approved by the FDA or EMA for human therapeutic use. All dosage information in this guide is derived from published preclinical research, Russian clinical study protocols, and the Khavinson Institute's institutional dosing frameworks. This content is for educational and research purposes only. Nothing here constitutes medical advice. Consult a licensed healthcare provider before considering any peptide protocol.
---
Pinealon — the synthetic Glu-Asp-Arg (EDR) tripeptide — occupies a distinctive niche in the Khavinson bioregulator family. While its sibling peptide Epitalon (AEDG) works upstream at the pineal gland to support melatonin synthesis and telomerase activation, Pinealon operates downstream at the neuron itself: modulating antioxidant defenses, protecting against hypoxic stress, and influencing the gene-regulatory pathways proposed to underpin neuronal longevity.
This guide synthesizes the available published dosing frameworks — primarily from Khavinson's Saint Petersburg Institute of Bioregulation and Gerontology — to provide researchers with a structured protocol reference for the EDR peptide. It should be read alongside the full Pinealon research profile, which covers mechanism, pharmacology, and the evidence base in depth.
---
What Is Pinealon (EDR) and Why Do Doses Matter?
Pinealon's sequence — L-Glutamic acid – L-Aspartic acid – L-Arginine (Glu-Asp-Arg) — makes it one of the smallest research peptides studied for central nervous system applications. Its low molecular weight (approximately 390 Da) means it can survive partial gastrointestinal digestion, and the small size facilitates proposed nuclear entry for the DNA-binding mechanism described by Khavinson and colleagues.
Because Pinealon is active at microgram-to-low-milligram concentrations and has been studied across multiple delivery routes with markedly different absolute dose ranges, understanding which protocol corresponds to which route is essential. A researcher comparing published "dose" numbers without route context can easily encounter a tenfold discrepancy — 0.2 mg/day (subcutaneous in one protocol) versus 20 mg/day (oral in another) — that is explained entirely by route and bioavailability differences.
CAS & Identity Verification
Before discussing dose, confirm you have authentic Pinealon: CAS 175175-23-2, sequence Glu-Asp-Arg, MW ≈ 390.35 Da. HPLC purity certificates from research suppliers should show ≥95% purity. Certificates of Analysis (CoA) confirming the correct sequence via mass spectrometry are the minimum QC standard for a research vial.
---
Reconstitution Protocol
Most commercial Pinealon vials contain 10 mg or 20 mg of lyophilized (freeze-dried) powder. The reconstitution approach is consistent across published research contexts.
Standard Reconstitution Steps
Supplies needed:
- •Bacteriostatic water (BAC water) — preferred for multi-use vials
- •Sterile water for injection — acceptable for single-use preparations
- •Alcohol wipes
- •Insulin syringe (29–31 gauge) or reconstitution syringe
Protocol:
1. Allow the vial to equilibrate to room temperature before opening (approximately 10–15 minutes if refrigerated).
2. Clean the rubber septum of the vial with an alcohol wipe and allow to dry.
3. Draw the target volume of BAC water into a syringe.
4. Inject the water slowly down the side wall of the vial — never directly onto the lyophilized cake. This prevents denaturation.
5. Gently swirl (do not shake) until the powder is fully dissolved. The solution should be clear and colorless.
6. Label the vial with the reconstitution date.
Recommended Dilution Ratios
| Vial Size | BAC Water Volume | Resulting Concentration | Volume per 100 mcg Dose |
|---|---|---|---|
| 10 mg | 2 mL | 5 mg/mL (5,000 mcg/mL) | 0.02 mL (2 units on insulin syringe) |
| 20 mg | 2 mL | 10 mg/mL | 0.01 mL (1 unit) |
| 20 mg | 4 mL | 5 mg/mL | 0.02 mL (2 units) |
The 2 mL per 20 mg vial concentration (10 mg/mL) is frequently cited in Khavinson group protocols and simplifies dose calculation. However, the 4 mL dilution (5 mg/mL) is easier to measure accurately with standard insulin syringes and reduces the risk of dosing errors at the low end of the research range.
Storage after reconstitution: Refrigerate at 2–8°C. Bacteriostatic water permits use within 28–30 days; sterile water preparations should be used within 24–48 hours.
---
Administration Routes and Dose Ranges
Published Pinealon research and institutional protocols from the Khavinson group describe three primary delivery routes. Each has a distinct dose range because bioavailability, absorption kinetics, and mechanism of action differ by route.
1. Subcutaneous Injection — The Primary Research Route
Subcutaneous (SC) administration is the most direct route documented in Khavinson-affiliated published studies and is the method that produces the most predictable systemic exposure.
Typical research dose range: 0.1 mg – 0.3 mg per administration (100–300 mcg)
Administration details:
- •Inject into subcutaneous fat of the abdomen, thigh, or back of the upper arm
- •Rotate injection sites to minimize local tissue stress
- •Use a 29–31 gauge insulin syringe; 0.5-inch needle is appropriate for most SC sites
- •Pinch skin and inject at 45–90° angle
Frequency: Once daily, typically in the morning or evening depending on research objective. For circadian-related protocols, some researchers use evening administration to align with the body's natural nocturnal melatonin synthesis window.
Why this range: At 0.1–0.3 mg SC, systemic exposure is sufficient for the neuroprotective endpoints documented in published preclinical work. Higher doses have been used in some animal studies without reported adverse events, but the human dose extrapolation logic points to this conservative range.
2. Intranasal Administration
Intranasal delivery is reported in research contexts because it offers a potential direct path to the central nervous system via olfactory nerve transport — an appealing hypothesis for a neuropeptide. However, published pharmacokinetic confirmation of intranasal CNS delivery is not yet established for EDR specifically.
Typical research dose range: 0.1 mg – 0.5 mg per session (100–500 mcg) intranasally
Administration details:
- •Reconstitute as above; the solution is drawn into a nasal spray atomizer or syringe
- •For atomizer delivery: prime the device, tilt head slightly forward, spray alternating nostrils
- •Sniff gently to distribute solution across nasal mucosa
- •Avoid blowing nose for 15–20 minutes post-administration
Note on high-dose oral/intranasal protocols: Some sources cite "20 mg/day" for oral or intranasal Pinealon. This reflects institutional multi-gram protocols from Russian clinical frameworks where oral bioavailability of peptides is compensated by dramatically higher doses. Researchers outside this institutional context typically work in the 0.1–0.5 mg intranasal range, which is more consistent with injectable pharmacological equivalents.
3. Sublingual Administration
Sublingual delivery allows the peptide to absorb directly through the sublingual mucosal vasculature, bypassing first-pass metabolism and providing more predictable exposure than swallowed oral forms.
Typical protocol: 100–200 mcg held under the tongue for 60–90 seconds before swallowing, 1–2 times daily.
Administration: Draw the target volume from the reconstituted vial, deposit under the tongue, hold for 60–90 seconds with minimal swallowing, then allow to drain or swallow.
Route Comparison Summary
| Route | Dose Range | Bioavailability | Primary Use Case |
|---|---|---|---|
| Subcutaneous | 0.1–0.3 mg/day | High (direct systemic) | Most published protocols |
| Intranasal | 0.1–0.5 mg/session | Moderate (mucosal) | CNS-targeted research |
| Sublingual | 0.1–0.2 mg/dose | Moderate (mucosal) | Alternative to injection |
---
Research Cycle Protocols
Pinealon is studied in defined cycles rather than continuous administration — consistent with the Khavinson group's framework for short-peptide bioregulators.
Standard Short Cycle (10 Days)
The most commonly cited protocol across published Khavinson work:
- •Duration: 10 consecutive days
- •Dose: 0.1–0.3 mg/day (SC) or 0.1–0.5 mg/day (intranasal)
- •Timing: Once daily, consistent time of day
- •Rest period: 1–3 months before repeating
This protocol mirrors the clinical trial design used in the published TBI-recovery study, which ran 20–30 days at 0.2 mg twice daily (oral).
Extended Cycle (20–30 Days)
Based on the published human clinical protocol for post-traumatic brain injury sequelae:
- •Duration: 20–30 days
- •Dose: 0.2 mg twice daily (oral in original trial; may be adapted for SC or sublingual)
- •Rest period: 2–3 months before repeating
- •Context: Higher-complexity research objectives involving cognitive or neurological endpoints
Quarterly Maintenance Protocol
Some researchers in longevity-oriented contexts use Pinealon as part of a quarterly bioregulator cycle alongside Epitalon and other Khavinson peptides:
- •Frequency: 4 times per year (approximately every 12–13 weeks)
- •Each cycle: 10 days, 0.1–0.2 mg/day SC
- •Rationale: Mirrors the seasonal rhythm logic proposed in Khavinson's broader bioregulator-cycling framework
---
Timing Considerations
Circadian Alignment
Given Pinealon's proposed influence on pineal gland biology and melatonin synthesis pathways, some research protocols consider timing relative to the light/dark cycle:
- •Evening administration: May be preferred for circadian-related research objectives, given that pineal melatonin synthesis is nocturnal. Administering Pinealon 1–2 hours before expected sleep onset aligns with the body's natural melatonin production window.
- •Morning administration: Used in neuroprotection-focused protocols where the goal is modulating daytime antioxidant enzyme expression rather than circadian endpoints.
No published study has directly compared morning versus evening Pinealon administration to confirm differential effects in humans. This remains a research hypothesis rather than established protocol guidance.
Stacking with Epitalon
Pinealon and Epitalon (AEDG) are the two most commonly co-researched Khavinson pineal bioregulators. The proposed rationale for combining them:
- •Epitalon acts upstream: stimulates the pineal gland's secretory function, supports telomerase activation, modulates melatonin output
- •Pinealon acts downstream: protects neurons receiving melatonin's signals, supports antioxidant enzyme expression, reduces neuronal senescence markers
Combination protocol used by some researchers:
- •10-day Epitalon cycle (0.5–1 mg/day SC)
- •Followed immediately by 10-day Pinealon cycle (0.1–0.2 mg/day SC)
- •Total cycle = 20 days; rest = 2–3 months
Alternatively, some protocols run both peptides simultaneously for 10 days. There is no published head-to-head comparison of sequential versus concurrent administration.
For the Epitalon protocol in detail, see the Epitalon (AEDG) Dosage Protocol Guide.
---
Pinealon Research Endpoints and Evidence Base
Understanding what published research has examined helps frame appropriate dosing contexts.
Neuroprotection (Primary Published Focus)
The majority of published Pinealon research addresses neuroprotection in models of:
- •Oxidative stress — reduced ROS, increased SOD2 (superoxide dismutase) expression in neuronal cultures
- •Hypoxic ischemia — reduced infarct volume in rodent cerebral ischemia models when administered prophylactically or post-insult
- •Neuronal senescence — altered PCNA and p21 expression in fibroblast-derived induced neurons (2024, International Journal of Molecular Sciences)
- •Alzheimer's-model dendritic spines — restored dendritic spine density in 5xFAD transgenic mouse model (2021)
- •TBI sequelae (human) — improved cognitive metrics in 72 patients with traumatic brain injury consequences at 0.2 mg twice daily oral, 20–30 days
Circadian and Melatonin-Related Research
Published animal studies have examined EDR in contexts of circadian disruption (shift-work simulation in rodents), where administration showed improvements in circadian rhythm regularity markers. The proposed mechanism — upregulation of serotonin synthesis as a melatonin precursor pathway — is mechanistically plausible but requires independent confirmation.
Evidence Quality Note
The published evidence base for Pinealon is dominated by research from Khavinson's group at the Saint Petersburg Institute of Bioregulation and Gerontology. While this represents a substantial body of preclinical and some clinical work, independent replication in Western research settings remains limited. The dose ranges presented in this guide are drawn from published protocols; they do not represent validated therapeutic doses.
---
Safety Profile and Monitoring in Research Contexts
Pinealon's safety data comes primarily from the same Khavinson group protocols. Published adverse event reporting is sparse, which reflects both the limited independent research base and the generally low doses used.
Reported observations in published protocols:
- •No significant adverse events reported at 0.1–0.3 mg/day SC in published studies
- •Oral administration at higher doses (institutional Russian protocols) noted no systemic toxicity signals
- •Local injection site reactions (erythema, mild swelling) are possible with any SC peptide administration
Parameters researchers monitor in published protocols:
- •Cognitive function assessments (relevant in TBI-context studies)
- •Sleep quality metrics (relevant in circadian-focused protocols)
- •Standard bloodwork baseline where other health parameters are relevant to the research design
What is not established: Long-term safety data beyond cycle durations studied, drug interaction profiles, safety in pregnancy, safety in pediatric populations, and pharmacokinetics (half-life, volume of distribution, confirmed CNS penetration) in humans.
---
Sourcing Considerations for Researchers
For researchers purchasing Pinealon, key quality markers include:
- •HPLC purity: ≥95%; ≥98% preferred for rigorous research
- •Mass spectrometry (MS) CoA: Confirms correct molecular weight (MW ≈ 390.35 Da) and sequence identity
- •Storage and cold chain: Lyophilized powder is stable at room temperature short-term; long-term storage should be ≤-20°C
- •Endotoxin testing: LAL (limulus amebocyte lysate) testing results on CoA add an additional quality layer for in-vivo research
Pinealon is typically sold in 10 mg and 20 mg vials. It is generally available from research peptide suppliers with active listings in the peptide marketplace.
---
Quick Reference Summary
| Parameter | Details |
|---|---|
| Peptide | Glu-Asp-Arg (EDR tripeptide) |
| CAS | 175175-23-2 |
| MW | ~390.35 Da |
| Routes | SC injection, intranasal, sublingual |
| SC dose range | 0.1–0.3 mg/day |
| Intranasal range | 0.1–0.5 mg/session |
| Typical cycle | 10 days on, 1–3 months off |
| Extended cycle | 20–30 days (per TBI clinical trial) |
| Reconstitution | 2–4 mL BAC water per 20 mg vial |
| Storage (reconstituted) | 2–8°C, use within 28 days (BAC water) |
| Primary research focus | Neuroprotection, circadian biology, cognitive function |
| Common co-research peptide | Epitalon (AEDG) |
---
Related Research
For the full mechanistic profile of Pinealon, including its proposed DNA-binding mechanism, circadian biology research, and comparison with other Khavinson bioregulators:
→ Pinealon (EDR Tripeptide) Complete Research Profile
For Epitalon dosage protocols and how it compares to Pinealon:
→ Epitalon (AEDG) Dosage Protocol Guide
---
This guide is provided for research and educational purposes only. Pinealon (EDR) is not approved by the FDA, EMA, or any comparable regulatory authority for human therapeutic use. All dosing information is derived from published preclinical and institutional research protocols. Nothing in this guide constitutes medical advice.